Joel Greenblatt's CRL Position Overview
Joel Greenblatt (via Gotham Asset Management, LLC) currently holds 315,755 shares of Charles River Laboratories International, Inc. (CRL) worth $49.4 M, representing 0.22% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 50 quarters.
Based on 13F filings since 2013, Joel Greenblatt has maintained a long-term strategic position in CRL, representing a significant commitment to this investment thesis. Largest addition occurred in Q2 2025, adding 114,384 shares. Largest reduction occurred in Q2 2017, reducing 113,999 shares.
Analysis based on 13F filings available since 2013 Q2
Joel Greenblatt's Charles River Laboratories International (CRL) Holding Value Over Time
Track share changes against reported price movement
Quarterly Charles River Laboratories International (CRL) Trades by Joel Greenblatt
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2013 | +50,188 | Add 0.00% | 50,187 | $41.03 |
| Q3 2013 | -8,733 | Reduce 17.40% | 41,454 | $46.27 |
| Q4 2013 | -19,695 | Reduce 47.51% | 21,759 | $53.04 |
| Q1 2014 | -21,759 | Sold Out | 21,759 | $0.00 |
| Q2 2014 | +11,280 | New Buy | 11,280 | $53.55 |
| Q3 2014 | -11,280 | Sold Out | 11,280 | $0.00 |
| Q4 2014 | +4,028 | New Buy | 4,028 | $63.56 |
| Q1 2015 | -4,028 | Sold Out | 4,028 | $0.00 |
| Q3 2015 | +29,055 | New Buy | 29,055 | $63.53 |
| Q4 2015 | -29,055 | Sold Out | 29,055 | $0.00 |
| Q1 2016 | +70,227 | New Buy | 70,227 | $75.94 |
| Q2 2016 | -58,371 | Reduce 83.12% | 11,856 | $82.41 |
| Q3 2016 | -11,856 | Sold Out | 11,856 | $0.00 |
| Q4 2016 | +2,750 | New Buy | 2,750 | $76.36 |
| Q1 2017 | +113,548 | Add 4129.02% | 116,298 | $89.95 |
| Q2 2017 | -113,999 | Reduce 98.02% | 2,299 | $101.35 |
| Q3 2017 | +43,607 | Add 1896.78% | 45,906 | $108.03 |
| Q4 2017 | -45,906 | Sold Out | 45,906 | $0.00 |
| Q1 2018 | +2,750 | New Buy | 2,750 | $106.91 |
| Q2 2018 | -2,750 | Sold Out | 2,750 | $0.00 |
| Q4 2018 | +33,905 | New Buy | 33,905 | $113.17 |
| Q1 2019 | -23,794 | Reduce 70.18% | 10,111 | $145.29 |
| Q2 2019 | -7,863 | Reduce 77.77% | 2,248 | $141.90 |
| Q3 2019 | -2,248 | Sold Out | 2,248 | $0.00 |
| Q4 2019 | +1,815 | New Buy | 1,815 | $152.62 |
| Q1 2020 | +26,665 | Add 1469.15% | 28,480 | $126.19 |
| Q2 2020 | -20,059 | Reduce 70.43% | 8,421 | $174.33 |
| Q3 2020 | +2,342 | Add 27.81% | 10,763 | $226.42 |
| Q4 2020 | -3,769 | Reduce 35.02% | 6,994 | $249.93 |
| Q1 2021 | -3,457 | Reduce 49.43% | 3,537 | $289.79 |
| Q2 2021 | +1,753 | Add 49.56% | 5,290 | $369.94 |
| Q3 2021 | +1,268 | Add 23.97% | 6,558 | $412.63 |
| Q4 2021 | -1,734 | Reduce 26.44% | 4,824 | $376.87 |
| Q1 2022 | +14,360 | Add 297.68% | 19,184 | $283.99 |
| Q2 2022 | -2,112 | Reduce 11.01% | 17,072 | $213.98 |
| Q3 2022 | -1,563 | Reduce 9.16% | 15,509 | $196.79 |
| Q4 2022 | -2,718 | Reduce 17.53% | 12,791 | $217.90 |
| Q1 2023 | +3,274 | Add 25.60% | 16,065 | $201.82 |
| Q2 2023 | -1,832 | Reduce 11.40% | 14,233 | $210.25 |
| Q3 2023 | +1,844 | Add 12.96% | 16,077 | $195.98 |
| Q4 2023 | +889 | Add 5.53% | 16,966 | $236.40 |
| Q1 2024 | +6,093 | Add 35.91% | 23,059 | $270.95 |
| Q2 2024 | +28,064 | Add 121.71% | 51,123 | $206.58 |
| Q3 2024 | +26,254 | Add 51.35% | 77,377 | $196.97 |
| Q4 2024 | +46,313 | Add 59.85% | 123,690 | $184.60 |
| Q1 2025 | +31,087 | Add 25.13% | 154,777 | $150.52 |
| Q2 2025 | +114,384 | Add 73.90% | 269,161 | $151.73 |
| Q3 2025 | +46,594 | Add 17.31% | 315,755 | $156.46 |
Joel Greenblatt's Charles River Laboratories International Investment FAQs
Joel Greenblatt first purchased Charles River Laboratories International, Inc. (CRL) in Q2 2013, acquiring 50,187 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt has held Charles River Laboratories International, Inc. (CRL) for 50 quarters since Q2 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt's largest addition to Charles River Laboratories International, Inc. (CRL) was in Q2 2025, adding 269,161 shares worth $40.84 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Joel Greenblatt's firm, Gotham Asset Management, LLC, owns 315,755 shares of Charles River Laboratories International, Inc. (CRL), valued at approximately $49.4 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Charles River Laboratories International, Inc. (CRL) represents approximately 0.22% of Joel Greenblatt's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt's peak holding in Charles River Laboratories International, Inc. (CRL) was 315,755 shares, as reported at the end of Q3 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.